Loading...
Symbols:
Loading...
Symbols:
WuXi PharmaTech (Cayman) Inc. (ADR) (WX)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on WuXi PharmaTech (Cayman) Inc. (ADR) (WX)
67 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on WX
- ChinaBio Today(45)
- Trader Mark(8)
- The Sun(3)
- Zachary Scheidt(2)
- SA Editor Abbi Adest(1)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(572)
- Trader Mark(490)
- SA Editor Eli Hoffmann(386)
- Stockerblog (164)
- SA Editor Miriam Metzinger(116)
Most commented on authors
- The Sun(15)
- ChinaBio Today(15)
- Trader Mark(11)
- Bespoke Investment Group(5)
- John Gilluly(5)
- China Bio in Review: More Fallout from Economic Crisis
- Wuxi, Pfizer Strengthen Relationship in New Deal
- China Biotech Week in Review: FDA, Deals & Earnings
- WuXi Expands J&J Collaboration
- WuXi Misses Q3 Forecast, Guides Lower for Year
- China Biotech in Review: Economic Trouble Here Too
- China Biotech in Review: Deals and Earnings
- Wuxi Pharma Drops on News of Deal Dissolution with Covance
- Yangtze River Delta Developing Huge R&D Base for Drug Companies
- China Biotech Week in Review: Earnings, Earnings, Earnings
- WuXi: Solid Earnings, Solid Outlook
- WuXi PharmaTech Earnings Seem Stellar
- Six Key Chinese Healthcare ADRs
- China ADRs: Mixed July
- Notes on a Worst-of-Breed Rally
- China ADRs: Severe Loss in June
- China Biotech in Review: A Week of Collaborations
- WuXi Partners with Covance on Contract Research Services in China
- Why I'm Cutting Wuxi Pharma Position Sharply
- Wuxi Pharma: Too Much of a Good Thing
- China Biotech Week in Review: Deals and Drugs
- WuXi PharmaTech Signs on for Three More Years with AstraZeneca
- China ADRs: Mixed May
- China Biotech Week in Review: Earnings, Deals and Drug Development
- Was WuXi PharmaTech’s Q1 Hurt by the AppTec Acquisition?
- WuXi Reports Another Improved Quarter
- WuXi Pharmatech Reports Another Healthy Quarter
- Why I'm Cutting WuXi PharmaTech
- China Biopharma: What’s Not to Like?
- WuXi PharmaTech Postpones Secondary Offering
- Biotech in Review: Positive Consolidation in China Life Science Companies
- China Biotech Week in Review: News on All Fronts
- WuXi PharmaTech Earmarks Proceeds from Share Offering for Facilities
- Earnings and More in China Biotech Weekly Review
- WuXi PharmaTech Beats Estimates: Should See Upside
- WuXi PharmaTech Drops Despite All the Good News
- China and the Virtualization of Biopharma
- WuXi PharmaTech: Poster Child for China’s CRO Industry
- China Biopharma Investing Looks Good for 2008
- WuXi PharmaTech Squeezes Suppliers
- US-Listed China Life Science Companies Fared Well in 2007
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »